Sweilem Rihani, PharmD, PhD is a clinical research scientist at the TRHC Precision Pharmacotherapy Research & Development Institute. Dr. Rihani received his PharmD from the University of Jordan in 2012 and his PhD in pharmacy from Auburn University-Alabama in 2019. Sweilem joined the PPRDI in July 2019 with three years of experience as a clinical pharmacist, in addition to his PhD in Pharmacy expertise in pre-clinical drug development, pharmacokinetics, DMPK, high-throughput screening, bioanalysis, and clinical pharmacology. During his PharmD education, he completed a two-year internship program at King Hussein Cancer Center (KHCC) in Amman-Jordan. He then started his career as a clinical pharmacist at KHCC, where he gained experience in pharmacotherapy, therapeutic drug monitoring, and dosing during several clinical rotations with highly qualified clinical pharmacists in the BMT-Unit, ICU, palliative care unit, chemotherapy-outpatient counseling, pediatrics, and internal medicine departments. Dr. Rihani has always been interested in clinical pharmacology, pharmacotherapy, drug discovery research and development, focusing on finding cure and managing challenging diseases. During his PhD, he worked on developing a high-throughput screening assay to identify drugs that rectify/protect the blood brain barrier (BBB) integrity from vascular amyloid toxicity associated with AD progression. In addition, his research focuses were to investigate the BBB and role of transport proteins/receptors in brain function and homeostasis. Dr. Rihani is the humble recipient of the 2017 Alzheimer’s Drug Discovery Foundation (ADDF) Young Investigator Scholarship, 2018 Rho Chi Pharmacy Honor Society Award, 2019 Center for Neuroscience initiative Graduate Research Award, 2019 Outstanding International Graduate Student Award, and honorable recipient of 2019 Auburn University Graduate School Student Marshal Award.